Soumen Bhattacharya: UC-II and Immune Modulation in Osteoarthritis
Soumen Bhattacharya, Lecturer at the Faculty of Physiology, RBC College for Women, shared a post on LinkedIn about an article by Ashim Gupta and Nicola Maffulli, published in Annals of Medicine, adding:
“Undenatured Type II Collagen (UC-II): A Novel Immunomodulatory Strategy in Osteoarthritis
Osteoarthritis (OA) is no longer viewed solely as a ‘wear-and-tear’ disease. Chronic low-grade inflammation plays a critical role in cartilage degradation, pain, stiffness, and progressive loss of joint function.
Recent evidence highlights an interesting therapeutic concept: Undenatured Type II Collagen (UC-II) works through oral immune tolerance, targeting inflammation rather than merely masking symptoms.
How does it work?
- UC-II reaches the Gut-Associated Lymphoid Tissue (GALT)
- Peyer’s patches recognize native Type II collagen epitopes
- Regulatory T cells (Tregs) are activated
- Tregs migrate to joints and release anti-inflammatory cytokines: Upregulates – IL-10, IL-4, TGF-β
Simultaneously suppress pro-inflammatory mediators: Suppresses – TNF-α, IL-1β, IL-6
Clinical Implications
Published studies have demonstrated:
- Reduced pain scores (VAS)
- Improved WOMAC scores
- Enhanced range of motion
- Better walking performance and mobility
- Improved quality of life
- Favorable safety profile
Why is this important?
Unlike conventional analgesics and NSAIDs that primarily address symptoms, UC-II may help modulate the immune response contributing to joint inflammation and cartilage degeneration.
As our understanding of osteoarthritis evolves, immune-targeted nutraceutical interventions may become valuable components of comprehensive OA management strategies.”
Title: Undenatured type II collagen for knee osteoarthritis
Authors: Ashim Gupta, Nicola Maffulli
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 13, 2026, 21:05Francisco Chacón-Lozsán: Heparin-Induced Thrombocytopenia – When an Anticoagulant Triggers Thrombosis
-
Oct 13, 2026, 21:04Aref Zribi: Isolated Tumor Thrombus and the Role of Prophylactic Anticoagulation
-
Oct 13, 2026, 21:01Alex Larson: Why Normal Bloodwork Does Not Always Tell the Whole Story
-
Oct 13, 2026, 20:58Juan Jauregui-Lozano: How Replication Stress Impairs Red Blood Cell Maturation
-
Oct 13, 2026, 20:55Caitlin Raymond: Understanding Platelet Refractoriness Before Ordering More Platelets
-
Oct 13, 2026, 20:54Sanja Seratlic: How Cow Feeding Systems Influence the Anti-Platelet Properties of Cheddar Cheese
-
Oct 13, 2026, 20:50Ruchika Goel: Cord Blood Red Blood Cells as a Physiologically Aligned Transfusion Strategy
-
Oct 13, 2026, 20:47Sophia Delicou: Strengthening Transfusion Safety Through Advanced Screening and Haemovigilance
-
Oct 13, 2026, 20:45Lydia Pecker: Alloimmunization and Transfusion Indications in Sickle Cell Disease Pregnancy